Stentys' self-expanding and drug-eluting stents demonstrate promising results in 'OPEN-I' clinical study

Medical device pioneer Stentys announced today that the complete ‘OPEN-I’ clinical study was presented by Stefan Verheye, M.D., Ph.D., at the Joint Interventional Meeting (“JIM”) 2010 in Rome, demonstrating superior results in 60 patients (27 Stentys drug-eluting stents and 33 Stentys bare-metal stents) who were followed–up angiographically after six months.

“We are actively pursuing our clinical program, particularly in the treatment of Acute Myocardial Infarction, to also prove the superiority of the Stentys technology in this additional group of patients.”

“These clinical results suggest very promising benefits for patients,” said Stefan Verheye, M.D., Ph.D., Department of Cardiology, Middelheim Hospital, Antwerp, Belgium. “We had already demonstrated that the self-expanding and disconnectable Stentys platform ensured optimal wall apposition and easy access to side branches. We can now confirm that the addition of a drug coating eliminates the need for reintervention.”

“These data fortify our conviction of the indisputable superiority of Stentys self-expanding and drug-eluting stents over balloon-expandable DES for the treatment of complex cases,” added Gonzague Issenmann, CEO and co-founder of Stentys. “We are actively pursuing our clinical program, particularly in the treatment of Acute Myocardial Infarction, to also prove the superiority of the Stentys technology in this additional group of patients.”

Source:

Stentys

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Transcranial ultrasound stimulation: A new frontier in noninvasive brain therapy